Диссертация (1174241), страница 18
Текст из файла (страница 18)
Teixeira, S.F. Metformin synergistically enhances antiproliferative effectsof cisplatin and etoposide in NCI-H460 human lung cancer cells / Teixeira S.F.,Guimarães Idos S., Madeira K.P., Daltoé R.D., Silva I.V. // J. Bras. Pneumol. –2013. – Vol. 39. – P. 644-649.2. Mendes, F. Lung cancer: the immune system and radiation / Mendes F.,Antunes C., Abrantes A.M., Gonçalves A.C., Nobre-Gois I., et al. // Br. J. Biomed.Sci. – 2015. – Vol. 72. – P. 78-84.3. Travis, W.D. Pathology of lung cancer / W.D. Travis // Clin. Chest. Med.– 2013.
– Vol. 32. – P. 669-692.4. Shimizu, K. Clinical significance of the tumor microenvironment in nonsmall cell lung cancer / Shimizu K., Okita R., Nakata M. // Ann. Transl. Med. –2013. – Vol. 1. – P. 8-10.5. Hespanhol, V. Cancro do pulmão no norte de Portugal?: um estudo debase hospitalar / Hespanhol V., Parente B., Araújo A., CunhaJ., FernandesA., et al.// Port. J. Pulmonol. – 2014. – Vol. 19. – P.
245-251.6. Longo, D.L. Harrison’s Principles of Internal Medicine, 18th edtn. / Longo D.L., Fauci A., Kasper D., Hauser S., Jameson J.L., et al. /McGraw-Hill, 2014.7. Davidson, M.R. The pivotal role of pathology in the management of lungcancer / Davidson M.R., Gazdar A.F., Clarke B.E. // J. Thorac.
Dis. – 2014. –Suppl. 5. – P. 463-478.8. Cagle, P.T. Revolution in lung cancer: new challenges for the surgical pathologist / Cagle P.T., Allen T.C., Dacic S., Beasley M.B., Borczuk A.C., et al. //Arch. Pathol. Lab. Med. – 2013. – Vol. 135. – P. 110-116.9. Andrews, T.D. Routinely obtained diagnostic material as a source of RNAfor personalized medicine in lung cancer patients / Andrews T.D., Baird J.W.,Wallace W.A., Harrison D.J. // J. Thorac.
Oncol. – 2012. – Vol. 6. – P. 884-888.12910. Raparia, K. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine / Raparia K., Villa C., DeCamp M.M., Patel J.D.,Mehta M.P.// Arch. Pathol. Lab. Med. – 2013. – Vol. 137. – P. 481-491.11. MacConaill, L.E. Advancing personalized cancer medicine in lung cancer / L.E. MacConaill // Arch. Pathol. Lab. Med.
– 2012. – Vol. 136. – P. 12101216.12. Yoshiyama, K. Personalized peptide vaccination in patients with refractory non-small cell lung cancer / Yoshiyama K., Terazaki Y., Matsueda S., Shichijo S., Noguchi M., et al. // Int. J. Oncol. – 2013. – Vol. 40. – P. 1492-1500.13. Mollberg, N.Mind-mapping for lung cancer: towards a personalized therapeutics approach / Mollberg N., Surati M., Demchuk C., Fathi R., Salama A.K.,et al. // Adv. Ther. – 2013. – Vol. 28. – P. 173-194.14.
Fortunato, O. Therapeutic use of microRNAs in lung cancer / FortunatoO., Boeri M., Verri C., Moro M., Sozzi G.L. // Biomed. Res. Int. 2014: 756975.15. Hammerschmidt, S. Lung Cancer: Current Diagnosis and Treatment /Hammerschmidt S., Wirtz H.// Dtsch. Arztebl. Int. – 2009. – Vol. 106. – P. 809821.16. Long, J.
Anticancer drug- loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis / Long J., CheangT., Zhuo S., Zeng R.F., Dai Q.S., et al. // J. Nanobiotechnology. – 2014. – Vol. 12.– P. 1-11.17. Tovar, I. Pattern of use of radiotherapy for lung cancer: a descriptivestudy / Tovar I., Expósito J., Jaén J., Alonso E., Martínez M., et al. // BMC Cancer.– 2014. – Vol. 14. – P. 697.18.
Parente Lamelas, I. Directed therapies in lung cancer: new hope? / Parente Lamelas I., Abal Arca J., Fírvida Pérez J.L.// Arch. Bronconeumol. – 2012. –Vol. 48. – P. 367-371.19.Chung, T.W. Induction of Indoleamine 2 , 3-dioxygenase ( IDO ) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Recetor 5 Expression in Human Non-small Cell Lung Cancer Cells / Chung T.W.,130Tan K., Chan H., Lai M.D., Yen M.C., et al. // Asian Pacific J. Cancer Prev.
–2014. – Vol. 15. – P. 7995-8001.20. Sklodkowska, J. Digital pathology in personalized cancer therapy /Sklodkowska J., Rojo M.G.// Folia Histochem. Cytobiol. – 2016. – Vol. 49. – P.570-578.21. Gold, K.A. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy / Gold K.A., Wistuba I.I., KimE.S.// Clin. Cancer Res. – 2014.
– Vol. 18. – P. 3002-3007.22. Roh, M.S. Molecular Pathology of Lung Cancer: Current Status and Future Directions / M.S. Roh // Korean Acad. Tuberc. Respir. Dis. – 2014. – Vol.3536. – P. 49-54.23. Villaruz, L.C. Personalized therapy for non-small cell lung cancer: whichdrug for which patient? / Villaruz L.C., Socinski M.A.// Semin.
Thorac. Cardiovasc. Surg. – 2015. – Vol. 23. – P. 281-290.24. Qu, Z. Grandinin down-regulates phosphorylation of epidermal growthfactor receptor / Qu Z., Song A., Feng W., Teng R., Gao J., et al. // Int. J. Clin.Exp. Pathol. – 2014. – Vol. 7. – P. 5888-5894.25. Liu, R. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel / Liu R., Liu X., Zheng Y., Gu J., Xiong S., et al. // Oncol.
Lett. – 2014. –Vol. 8. – P. 2193-2200.26. West, L. A novel classification of lung cancer into molecular subtypes /West L., Vidwans S.J., Campbell N.P., Shrager J., Simon G.R., et al. // PLoS One7. – 2012. – e31906.27. Antonicelli, A. EGFR-targeted therapy for non-small cell lung cancer:focus on EGFR oncogenic mutation / Antonicelli A., Cafarotti S., Indini A., GalliA., Russo A., et al.
// Int. J. Med. Sci. – 2013. – Vol. 10. – P. 320-330.28. Asami, K. Epidermal growth factor receptor tyrosine kinase inhibitorsfor non-small cell lung cancer / Asami K., Atagi S.// World J. Clin. Oncol. – 2014.– Vol. 5. – P. 646-659.13129. Chen, L.
Predictive factors associated with gefitinib response in patientswith advanced non-small-cell lung cancer (NSCLC) / Chen L., Chen R., Zhu Z.,Zhang Y., Wen Z., et al. // Chin. J. Cancer. Res. – 2014. – Vol. 26. – P. 466-470.30. Varella-Garcia, M. Chromosomal and genomic changes in lung cancer /M. Varella-Garcia // Cell Adh. Migr. – 2016. – Vol. 4. – P. 100-106.31. Planchard, D. Identification of driver mutations in lung cancer: first stepin personalized cancer / D. Planchard // Target Oncol.
– 2014. – Vol. 8. – P. 3-14.32. Cheng, L. Molecular pathology of lung cancer: key to personalized medicine / Cheng L., Alexander R.E., Maclennan G.T., Cummings O.W., MontironiR., et al. // Mod. Pathol.– 2012. – Vol. 25. – P. 347-369.33. Chen, J. Therapeutic effects and adverse drug reactions are affected byicotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small celllung cancer patients / Chen J., Zheng X., Liu D.Y., Zhao Q., Wu Y.W., et al. //Asian Pac.
J. Cancer Prev. – 2014. – Vol. 15. – P. 7195-7200.34. Heuvers, M.E. Patient-tailored modulation of the immune system mayrevolutionize future lung cancer treatment / Heuvers M.E., Aerts J.G., CornelissenR., Groen H., Hoogsteden H.C., et al. // BMC Cancer. – 2015. – Vol. 12. – P. 580.35. de Mello, R.A. Insights into angiogenesis in non-small cell lung cancer:molecular mechanisms, polymorphic genes, and targeted therapies / de Mello R.A.,Costa B.M., Reis R.M., Hespanhol V.// Recent Pat. Anticancer.
Drug Discov. –2012. – Vol. 7. – P. 118-131.36. Hartel, P.H. Toward Personalized Medicine of Lung Cancer?: Responseto Nontargeted Therapy in Invasive Pulmonary Adenocarcinoma as a Function ofTumor Cell Differentiation / Hartel P.H., Hartel J.V., Fanburg-Smith J.C., Julie C.,Gilmore R.W., et al. // Int. J. Surg. Pathol. – 2013. – Vol. 21. – P. 224-228.37.Symposium L. Personalized medicine: Lung Cancer leads the way // Indian J.
Cancer. 50: 2013-2015.38. Shaw, A.T. Crizotinib in ROS1 -Rearranged Non-Small-Cell Lung Cancer / Shaw A.T., Ou S.-H.I., Bang Y.J., R. Camidge, B. J. Solomon, et al. // N.Engl. J. Med. – 2014. – Vol. 371. – P. 1963-1971.13239. Nishino, M. Personalized Tumor Response Assessment in the Era ofMolecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria toComplement Pitfalls of RECIST / Nishino M., Jagannathan J.P., Krajewski K.M.,O’Regan K., Hatabu H., et al. // AJR Am.
J. Roentgenol. – 2013. – Vol. 198. – P.737-745.40. Kobayashi, K. Epidermal growth factor receptor (EGFR) mutation andpersonalized therapy in advanced nonsmall cell lung cancer (NSCLC) / KobayashiK., Hagiwara K. // Target Oncol. – 2013. – Vol. 8. – P. 27-33.41. Moreira, A.L. Personalized Medicine for Non - Small- Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing / Moreira A.L., Thornton R.H.// CLLC. – 2013. – Vol. 13. – P.334-339.42.
Haghgoo, S.M. Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer / Haghgoo S.M., Allameh A., Mortaz E.,Garssen J., Folkerts G., et al. // Eur. J Pharmacol. – 2015. – Vol. 754. – P. 82-91.43. Okimoto, R.A. Recent advances in personalized lung cancer medicine /Okimoto R.A., Bivona T.G.// Per. Med. – 2013. – Vol. 11. – P. 309-321.44. Forde, P.M. Targeted therapy for non-small-cell lung cancer: past,present and future / Forde P.M., Ettinger D.S.// Expert Rev.
Anticancer. Ther. –2013. – Vol. 13. – P. 745-758.45. Dienstmann, R. Personalizing therapy with targeted agents in non-smallcell lung cancer / Dienstmann R., Martinez P., Felip E.// Oncotarget. – 2015. –Vol. 2. – P. 165-177.46. Cagle, P.T. Lung cancer biomarkers: present status and future developments / Cagle P.T., Allen T.C., Olsen R.J.//Arch. Pathol. Lab. Med. – 2013. – Vol.137.
– P. 1191-1198.47. Girard, N.Other signalization targets / N. Girard // Target Oncol. – 2013.– Vol. 8. – P. 69-77.48. Kerr, K.M. Personalized medicine for lung cancer: new challenges forpathology / K.M. Kerr // Histopathology. – 2012. – Vol. 60. – P. 531-546.13349. Kim, H.S. Personalized therapy on the horizon for squamous cell carcinoma of the lung / Kim H.S., Mitsudomi T., Soo R.A., Cho B.C.// Lung Cancer. –2012. – Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
